Introduction：Basic information about CAS 144494-65-5|Tirofiban, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Tirofiban |
|---|
| CAS Number | 144494-65-5 | Molecular Weight | 440.597 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 611.7±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C22H36N2O5S | Melting Point | 223-225ºC |
|---|
| MSDS | / | Flash Point | 323.7±34.3 °C |
|---|
Names
| Name | tirofiban |
|---|
| Synonym | More Synonyms |
|---|
Tirofiban BiologicalActivity
| Description | Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistTarget: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml). |
|---|
| Related Catalog | Signaling Pathways >>Cytoskeleton >>IntegrinResearch Areas >>Cardiovascular Disease |
|---|
| References | [1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 611.7±65.0 °C at 760 mmHg |
|---|
| Melting Point | 223-225ºC |
|---|
| Molecular Formula | C22H36N2O5S |
|---|
| Molecular Weight | 440.597 |
|---|
| Flash Point | 323.7±34.3 °C |
|---|
| Exact Mass | 440.234497 |
|---|
| PSA | 113.11000 |
|---|
| LogP | 4.14 |
|---|
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.532 |
|---|
| InChIKey | COKMIXFXJJXBQG-NRFANRHFSA-N |
|---|
| SMILES | CCCCS(=O)(=O)NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O |
|---|
| Storage condition | -20°C |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| Risk Phrases | 36/37/38 |
|---|
| Safety Phrases | S22-S26-S30-S36/37/39-S45 |
|---|
| RIDADR | UN3261 |
|---|
| Packaging Group | II |
|---|
| Hazard Class | 8 |
|---|
| HS Code | 2942000000 |
|---|
Customs
Synonyms
| Tirofiban [BAN:INN] |
| N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine |
| N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)butyl)-(S)-tyrosine |
| MFCD05237246 |
| 2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid |
| (S)-2-(butane-1-sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)phenyl]-propionic acid |
| Agrastat |
| Agrastat (TN) |
| N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid |
| UNII-GGX234SI5H |
| Aggrastat |
| Tirofiban |
| Tirofiban (INN) |
| Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]- |
| (2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid |
| N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE |
| L-tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]- |
| L700462 |
| MK383 |
